Gilead Sciences
49
175M
38
1.32
6
0.22
11
- Areas of investment
Summary
In 1987 was created Gilead Sciences, which is appeared as Corporate Investor. The main office of represented Corporate Investor is situated in the Foster City. The venture was found in North America in United States.
We also calculated 4 valuable employees in our database.
The typical case for the fund is to invest in rounds with 6-7 participants. Despite the Gilead Sciences, startups are often financed by Penn Medicine Co-Investment Fund, Parker Institute for Cancer Immunotherapy, Lilly Asia Ventures. The meaningful sponsors for the fund in investment in the same round are Be The Match BioTherapies, Yonghua Capital, Ping An Ventures. In the next rounds fund is usually obtained by Penn Medicine Co-Investment Fund, Be The Match BioTherapies, venBio Select Advisor.
Deals in the range of more than 100 millions dollars are the general things for fund. The fund is constantly included in 2-6 investment rounds annually. Opposing the other organizations, this Gilead Sciences works on 4 percentage points more the average amount of lead investments. The high activity for fund was in 2019. The increased amount of exits for fund were in 2019.
For fund there is a match between the location of its establishment and the land of its numerous investments - United States. Among the most successful fund investment fields, there are Nanotechnology, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight Allogene Therapeutics, AlloVir, Lyndra Therapeutics. The fund has no exact preference in a number of founders of portfolio startups. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund.
Investments analytics
Analytics
- Total investments
- 49
- Lead investments
- 6
- Exits
- 11
- Rounds per year
- 1.32
- Follow on index
- 0.22
- Investments by industry
- Biotechnology (34)
- Health Care (28)
- Therapeutics (18)
- Medical (12)
- Pharmaceutical (8) Show 21 more
- Investments by region
-
- Belgium (1)
- United States (45)
- United Kingdom (1)
- Austria (1)
- Peak activity year
- 2023
- Number of Unicorns
- 1
- Number of Decacorns
- 1
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 13
- Avg. valuation at time of investment
- 24M
- Group Appearance index
- 0.51
- Avg. company exit year
- 4
- Avg. multiplicator
- 0.23
- Strategy success index
- 0.60
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Tentarix Biotherapeutics | 06 Sep 2023 | Biotechnology | Early Stage Venture | 35M | United States, California, La Jolla |
| Tmunity Therapeutics | 19 Apr 2018 | Biotechnology, Health Care, Genetics, Manufacturing, Therapeutics | Early Stage Venture | 35M | United States, Pennsylvania, Philadelphia |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.